MYND Life Sciences closes fully subscribed $3 million non-brokered private placement

September 9, 2021

On September 9, 2021, MYND Life Sciences Inc. (CSE: MYND) (OTC: MYNDF) (“MYND”) completed its non-brokered private placement offering under which it sold $3,000,000 aggregate principal amount of convertible debenture units (the “Debenture Units”) for gross proceeds of $2,700,000.

Each Debenture Unit consists of (i) $1,000 principal amount of senior unsecured convertible debentures; and (ii) common share purchase warrants exercisable for 1,000 common shares in MYND.

MYND Life Sciences is a medicinal biotech and drug research and development company focused on neuro-pharmaceutical and novel psychedelic drug development, diagnostic approaches and vaccines.

Miller Thomson advised MYND with a team comprised of Rhea Solis, John-David D’Souza (Capital Markets & Securities) and Anca Nitu (Paraprofessional).